Dan Skovronsky, Eli Lilly CSO (Lilly via Facebook)

Eli Lil­ly tees up dis­cov­ery pact worth more than $1.6B with Merus for T cell-fo­cused bis­pe­cif­ic an­ti­bod­ies

Un­der sci­ence chief Dan Skovron­sky, Eli Lil­ly has tak­en some big swings at next-gen ther­a­pies, in­clud­ing try­ing to find the next big thing in on­col­o­gy. Now, af­ter one ear­ly fail­ure in the field, Lil­ly is go­ing back to the bis­pe­cif­ic an­ti­body well with a new deal with a Dutch biotech.

Lil­ly will pay $40 mil­lion up­front with an ad­di­tion­al $20 mil­lion eq­ui­ty stake in Merus NV to iden­ti­fy and de­vel­op three bis­pe­cif­ic an­ti­bod­ies look­ing to en­gage the CD3 anti­gen on T cells and redi­rect im­mune cells, the In­di­anapo­lis phar­ma gi­ant said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.